Chronic kidney disease affects more than 850 million people worldwide and continues to impose a heavy clinical and economic burden. Despite its scale, progress in kidney disease research and drug development lags behind other therapeutic areas.
Employers are an essential part of the UK’s health system, filling gaps with private cover for their staff. Weakening their ability to do this means pushing more people onto NHS waiting lists